Quillien V, Raoul J L, Laurent J F, Meunier B, Le Prise E
Department of Clinical Biology, Centre regional de lutte contre le cancer, 35062 Rennes, France.
Oncol Rep. 1998 Nov-Dec;5(6):1561-5. doi: 10.3892/or.5.6.1561.
The tumor markers Cyfra 21-1, TPA and SCC were assayed in a series of 96 patients with squamous cell carcinoma of the esophagus. Sensitivity was 42% for Cyfra 21-1, 40% for TPA and 37% for SCC. Combining Cyfra 21-1 and SCC gave a 56% sensitivity and combining TPA and SCC a 58% sensitivity. Sensitivity varied with disease stage and was particularly good in stage IV disease. Tumor markers did not vary with tumor differentiation. SCC levels were higher in tumors in the upper third of the esophagus. Pre-treatment levels of Cyfra 21-1 correlated with histological response. Cyfra 21-1 was also the only marker which distinguished significantly different survival curves. In multivariate analysis, however, treatment was the only independent factor predictive of survival.
对96例食管鳞状细胞癌患者进行了细胞角蛋白19片段（Cyfra 21-1）、组织多肽抗原（TPA）和鳞状细胞癌抗原（SCC）等肿瘤标志物检测。Cyfra 21-1的敏感性为42%，TPA为40%，SCC为37%。Cyfra 21-1与SCC联合检测敏感性为56%，TPA与SCC联合检测敏感性为58%。敏感性随疾病分期而异，在IV期疾病中尤其高。肿瘤标志物与肿瘤分化无关。食管上段肿瘤的SCC水平较高。Cyfra 21-1的治疗前水平与组织学反应相关。Cyfra 21-1也是唯一能显著区分不同生存曲线的标志物。然而，在多变量分析中，治疗是预测生存的唯一独立因素。
